Gastric adenocarcinoma of the fundic gland: A review of clinicopathological characteristics, treatment and prognosis

Abstract

Gastric adenocarcinoma of the fundic gland is a rare, well-differentiated gastric cancer entity, and very few patients transition to poorly differentiated tubular adenocarcinoma during progression. Gastric adenocarcinoma of the fundic gland originates from the mucosa of the gastric fundic gland, usually without chronic gastritis or intestinal metaplasia. Histologically, the tumor cells are closely arranged to form anastomosing tubular glands, and more than 95% of tumor cells differentiate towards chief cells. Most gastric adenocarcinoma of the fundic gland cases are characterized by submucosal involvement, but the tumor volume is usually small, with lymphatic and vascular invasion rarely observed. Therefore, endoscopic submucosal dissection can be an ideal treatment, leading to a favorable prognosis, and recurrence and metastasis of the disease are uncommon.

Identification of GNG7 as a novel biomarker and potential therapeutic target for gastric cancer via bioinformatic analysis and in vitro experiments

“…GC is one of the most prevalent and deadliest malignancies and the main cause of tumor-associated death worldwide [ 1 ]. Although tremendous advances have been made in the prevention and management of GC in recent decades, the prognosis and quality of life of patients diagnosed with GC remain dismal [ 5 , 6 ]. The diagnostic abilities of traditional tumor markers such as CEA, CA 125, CA19-9 and CA 72-4 for GC are largely limited owing to their inadequate sensitivity or specificity [ 34 , 35 ].…”

“…Besides, the different levels of metastases and postoperative recurrence rates remain the predominant contributing factors in the invalidity or failure of clinical treatment [ 4 ]. The 5-year overall survival rate of patients with localized GC can reach 90%; however, the same rate in patients with progressive stages is usually <5% [ 5 , 6 ]. Therefore, it is imperative for researchers to find novel biomarkers and effective targets for improving the early diagnosis rate and clinical outcomes of patients with GC.…”

Oxyntic Gland Adenoma in a Patient With Refractory Reflux

“…Various patterns have been described. The chief cell-predominant pattern is by far the most common (96%-99%) [ 10 , 12 ] and consists of highly differentiated columnar cells with either pale blue or eosinophilic cytoplasm in the typical or eosinophilic variants, respectively. Other patterns include tumors with both chief cells and parietal cells, known as the mixed cell pattern, parietal cell-predominant pattern, as well as tumors containing both the chief cell-predominant and mixed cell patterns [ 1 , 10 ].…”

Prognostic value of antitumor drug targets prediction using integrated bioinformatic analysis for immunogenic cell death-related lncRNA model based on stomach adenocarcinoma characteristics and tumor immune microenvironment

“…Patients are typically identified at an advanced phase, with a dismal prognosis. Patients with advanced STAD typically have a 5-year survival rate fewer than 5% (Meng et al, 2021). Molecular mechanisms underlying STAD still have not been fully clarified.…”